Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Accumulated Expenses: 2013-2020

Historic Accumulated Expenses for Fortress Biotech (FBIO) over the last 8 years, with Dec 2020 value amounting to $45.4 million.

  • Fortress Biotech's Accumulated Expenses rose 292.08% to $82.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $82.9 million, marking a year-over-year increase of 292.08%. This contributed to the annual value of $45.4 million for FY2020, which is 78.70% up from last year.
  • According to the latest figures from FY2020, Fortress Biotech's Accumulated Expenses is $45.4 million, which was up 78.70% from $25.4 million recorded in FY2019.
  • In the past 5 years, Fortress Biotech's Accumulated Expenses ranged from a high of $45.4 million in FY2020 and a low of $11.9 million during FY2016.
  • Its 3-year average for Accumulated Expenses is $29.0 million, with a median of $25.4 million in 2019.
  • As far as peak fluctuations go, Fortress Biotech's Accumulated Expenses fell by 7.21% in 2018, and later soared by 78.70% in 2020.
  • Fortress Biotech's Accumulated Expenses (Yearly) stood at $11.9 million in 2016, then surged by 47.67% to $17.6 million in 2017, then declined by 7.21% to $16.4 million in 2018, then skyrocketed by 55.25% to $25.4 million in 2019, then soared by 78.70% to $45.4 million in 2020.